Quantum Biopharma (NASDAQ:QNTM) Issues Quarterly Earnings Results, Beats Estimates By $0.44 EPS

Quantum Biopharma (NASDAQ:QNTM – Get Free Report) announced its earnings results on Thursday. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.44, FiscalAI reports.

Quantum Biopharma Trading Down 8.2%

Shares of NASDAQ QNTM traded down $0.16 during midday trading on Thursday, reaching $1.78. The company had a trading volume of 278,826 shares, compared to its average volume of 91,491. The business’s 50-day simple moving average is $2.92 and its 200 day simple moving average is $3.69. Quantum Biopharma has a 1 year low of $1.71 and a 1 year high of $12.42.

Analysts Set New Price Targets

Several brokerages have weighed in on QNTM. Rodman & Renshaw began coverage on Quantum Biopharma in a report on Monday, August 31st. They issued a “buy” rating and a $8.00 price target for the company. Weiss Ratings downgraded shares of Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, November 2nd. Finally, Wall Street Zen upgraded shares of Quantum Biopharma from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $8.00.

Get Our Latest Stock Analysis on Quantum Biopharma

About Quantum Biopharma

(Get Free Report)

Quantum BioPharma Ltd. is a biotechnology company focused on developing treatments for neurodegenerative and neurological disorders. Its lead drug candidate, Lucid-21-302, also known as Lucid-MS, is an orally administered small molecule being developed as a potential therapy for multiple sclerosis. The company is investigating the compound’s ability to protect nerve cells and promote remyelination, or the repair of damaged myelin. Quantum BioPharma is also pursuing additional applications for its drug-development platform, including potential treatments for other neurodegenerative and mental health conditions.

Read More

Earnings History for Quantum Biopharma (NASDAQ:QNTM)

Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.